Skip to content

Clinical trials

Stomach Neoplasms trials in the United Kingdom

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Stomach Neoplasms Country / region: United Kingdom Clear all

152 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20011
20022
20042
20053
20061
20073
20082
20092
20103
20115
20128
20132
20146
20154
20164
20179
201815
201910
202011
20218
202215
202310
202411
20256
20265

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed59
Recruiting30
Terminated22
Active, not recruiting19
Unknown status19
Not yet recruiting2
Suspended1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
AstraZeneca13
Royal Marsden NHS Foundation Trust11
Cancer Research UK7
Imperial College London6
Amgen4
Hoffmann-La Roche4
Merck Sharp & Dohme LLC4
Novartis Pharmaceuticals4
Seagen, a wholly owned subsidiary of Pfizer4
Taiho Oncology, Inc.4

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Stomach Neoplasms152
Esophageal Neoplasms50
Carcinoma, Non-Small-Cell Lung30
Ovarian Neoplasms24
Colorectal Neoplasms22
Pancreatic Neoplasms21
Triple Negative Breast Neoplasms18
Endometrial Neoplasms16
Neoplasms16
Squamous Cell Carcinoma of Head and Neck16

Trials

Showing 1 to 25 of 152. Each trial links to its page on Pharma Observatory.

52 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.